PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ...
The latest analyst update for Pacific Biosciences of California cuts the rating to Underweight and trims the price target from US$2 to US$1.50, while keeping a fair value estimate of US$2.43 per share ...
StockStory.org on MSN
Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna shares plummet, what you need to know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...
(RTTNews) - PacBio (PACB), a developer of highly accurate sequencing solutions, is slated to participate in several upcoming investor conferences this month, underscoring its visibility within the ...
MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...
MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year ...
Zacks Investment Research on MSN
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that Basecamp Research has ...
PacBio reports that through its partnership with China-headquartered Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration approval from the National Medical ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong third-quarter results, is expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results